DIATEST - mHealth and Type 2 Diabetes Mellitus (DIATEST)
Primary Purpose
Diabetes Mellitus, Type 2
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
FoodSwitch
Sponsored by
About this trial
This is an interventional other trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion Criteria: age 18-75 years regularly participate in grocery shopping self-report of having T2DM, with or without diabetes medication Exclusion Criteria: no access to BankID (a digital identification system commonly used in Sweden), thus unable to consent to the study fail to complete the run-in procedures HbA1c <48 mmol/mol in combination with no ongoing diabetes treatment
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
Intervention
Control
Arm Description
Access to the 'DiabetesSwitch' filter of the FoodSwitch app when food shopping during 26 weeks.
Access to written dietary advice during 26 weeks.
Outcomes
Primary Outcome Measures
HbA1c (mmol/mol)
Hemoglobin A1C (mmol/mol)
Secondary Outcome Measures
Total cholesterol (mmol/l)
Total cholesterol (mmol/l)
LDL (mmol/l)
Low-density lipoprotein (mmol/l)
HDL (mmol/l)
High-density lipoprotein (mmol/l)
eGFR (ml/min)
Estimated glomerular filtration rate (ml/min)
TNF-α (ng/L)
Tumor necrosis factor - alpha (ng/L)
IL-1β (ng/L)
Interleukin 1β (ng/L)
IL-6 (ng/L)
Interleukin 6 (ng/L)
hsCRP (mg/L)
High sensitive c-reactive protein (mg/L)
Proteomics, and metabolomics
The analysis of proteomics and metabolomics is explorative, and therefore the selection of proteins and metabolites is not pre-determined but will rather include those that are available and deemed appropriate at the time of analysis
Albuminuria (mg/l)
Albuminuria (mg/l)
Self-measured waist circumference (cm)
Self-measured waist circumference (cm)
Self-reported quality of life
Self-reported quality of life - questionnaire
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05977218
Brief Title
DIATEST - mHealth and Type 2 Diabetes Mellitus
Acronym
DIATEST
Official Title
DIATEST - a mHealth Intervention to Improve Clinical Management of Type 2 Diabetes Mellitus
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
January 1, 2024 (Anticipated)
Primary Completion Date
December 31, 2029 (Anticipated)
Study Completion Date
December 31, 2029 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Linkoeping University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Dietary modification is effective in the prevention and treatment of type 2 diabetes mellitus (T2DM). However, the access to dieticians in primary care is limited. While mHealth tools have been shown to improve diet and clinical management of patients with T2DM, there are currently no mobile health (mHealth) tools that are effective in improving diet and clinical management of T2DM in Sweden. The aim of this project is to study the effect of the FoodSwitch app, an mHealth intervention for patients with T2DM.
Detailed Description
This randomized controlled trial will determine the effect of the FoodSwitch app for healthier food choices on HbA1c, blood lipids, renal function and low-grade inflammation in individuals with T2DM. The effect of the mHealth tool on HbA1c and cardiovascular risk factors, will be compared to standard dietary advice for patients with T2DM. Randomization will be performed in a 1:1 ratio to receive the FoodSwitch app intervention or control and stratified by age (<50 years/≥50 years), sex, and baseline insulin use (Yes/No). The intervention group will scan all their purchased packaged food with the FoodSwitch app for one week at 6 and 12, 18 and 26 weeks. The control group will photograph and upload images of their receipts or share digital shopping receipts for one week at 6 and 12, 18 and 26 weeks. All participants in both the intervention and control group will report symptoms, functions, and quality of life, as often as they like as well as at 6 and 12, 18 and 26 weeks. All participants will be mailed a blood and urine collection kit and instructed to use it and to self-measure waist circumference at the start of the study and at 26 weeks. The primary outcome (HbA1c) and secondary outcomes (blood measurements of total cholesterol, LDL and HDL cholesterol, eGFR, TNF-α, IL-1β, IL-6, CRP, proteomics, and metabolomics; microalbuminuria; self-measured waist circumference; self-reported quality of life, 24-hour dietary recall, as well as other present symptoms; smartphone-obtained physical activity levels and patterns) will be evaluated at 26 weeks. National registry-obtained data on medication use, hospitalizations and deaths will also be evaluated.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
900 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Intervention
Arm Type
Experimental
Arm Description
Access to the 'DiabetesSwitch' filter of the FoodSwitch app when food shopping during 26 weeks.
Arm Title
Control
Arm Type
No Intervention
Arm Description
Access to written dietary advice during 26 weeks.
Intervention Type
Other
Intervention Name(s)
FoodSwitch
Intervention Description
Access to the 'DiabetesSwitch' filter of the FoodSwitch app when food shopping. When a packaged food item bar code is scanned, the FoodSwitch app will show an interpretive nutritional information score for the scanned product and recommend alternate healthier food options in the same category.
Primary Outcome Measure Information:
Title
HbA1c (mmol/mol)
Description
Hemoglobin A1C (mmol/mol)
Time Frame
Change from baseline at week 26
Secondary Outcome Measure Information:
Title
Total cholesterol (mmol/l)
Description
Total cholesterol (mmol/l)
Time Frame
Change from baseline at week 26
Title
LDL (mmol/l)
Description
Low-density lipoprotein (mmol/l)
Time Frame
Change from baseline at week 26
Title
HDL (mmol/l)
Description
High-density lipoprotein (mmol/l)
Time Frame
Change from baseline at week 26
Title
eGFR (ml/min)
Description
Estimated glomerular filtration rate (ml/min)
Time Frame
Change from baseline at week 26
Title
TNF-α (ng/L)
Description
Tumor necrosis factor - alpha (ng/L)
Time Frame
Change from baseline at week 26
Title
IL-1β (ng/L)
Description
Interleukin 1β (ng/L)
Time Frame
Change from baseline at week 26
Title
IL-6 (ng/L)
Description
Interleukin 6 (ng/L)
Time Frame
Change from baseline at week 26
Title
hsCRP (mg/L)
Description
High sensitive c-reactive protein (mg/L)
Time Frame
Change from baseline at week 26
Title
Proteomics, and metabolomics
Description
The analysis of proteomics and metabolomics is explorative, and therefore the selection of proteins and metabolites is not pre-determined but will rather include those that are available and deemed appropriate at the time of analysis
Time Frame
Change from baseline at week 26
Title
Albuminuria (mg/l)
Description
Albuminuria (mg/l)
Time Frame
Change from baseline at week 26
Title
Self-measured waist circumference (cm)
Description
Self-measured waist circumference (cm)
Time Frame
Change from baseline at week 26
Title
Self-reported quality of life
Description
Self-reported quality of life - questionnaire
Time Frame
Change from baseline at week 26
Other Pre-specified Outcome Measures:
Title
24-hour dietary recall
Description
24-hour dietary recall
Time Frame
Change from baseline at week 26
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
age 18-75 years
regularly participate in grocery shopping
self-report of having T2DM, with or without diabetes medication
Exclusion Criteria:
no access to BankID (a digital identification system commonly used in Sweden), thus unable to consent to the study
fail to complete the run-in procedures
HbA1c <48 mmol/mol in combination with no ongoing diabetes treatment
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lana Hebib, MD
Phone
013-28 10 00
Email
lana.hebib@liu.se
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Karin Rådholm, MD, PhD
Organizational Affiliation
Linkoeping University
Official's Role
Study Director
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Time Frame
After publication in a peer-reviewed journal and for the period of time for which local archive regulations stipulate.
IPD Sharing Access Criteria
To be determined on a case by case basis.
Citations:
PubMed Identifier
25147135
Citation
Dunford E, Trevena H, Goodsell C, Ng KH, Webster J, Millis A, Goldstein S, Hugueniot O, Neal B. FoodSwitch: A Mobile Phone App to Enable Consumers to Make Healthier Food Choices and Crowdsourcing of National Food Composition Data. JMIR Mhealth Uhealth. 2014 Aug 21;2(3):e37. doi: 10.2196/mhealth.3230.
Results Reference
background
PubMed Identifier
26819969
Citation
Coughlin SS, Whitehead M, Sheats JQ, Mastromonico J, Hardy D, Smith SA. Smartphone Applications for Promoting Healthy Diet and Nutrition: A Literature Review. Jacobs J Food Nutr. 2015;2(3):021.
Results Reference
background
Learn more about this trial
DIATEST - mHealth and Type 2 Diabetes Mellitus
We'll reach out to this number within 24 hrs